Professor of Medicine
Baylor College of Medicine
Baylor College of Medicine
Houston, Texas, United States
Christie Ballantyne is one of the nation’s foremost experts on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte-endothelial interactions, translations research in biomarkers and clinical trials.
Over the past 34 years, his many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012 he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Christie as one of “The World's Most Influential Scientific Minds.”
With over 600 publications in the area of atherosclerosis, lipids and inflammation, Christie also serves as an Editorial Director for www.lipidsonline.org as well as serving on the Editorial Board for Circulation. Christie is the Vice Chair of Research for the Department of Medicine, the Chief of Cardiology and the Chief of Cardiovascular Research at Baylor College of Medicine. He is currently the Director of the Lipid Metabolism and Atherosclerosis Clinic Center for Cardiometabolic Disease Prevention at Baylor College of Medicine.
Christie received his MD from Baylor College of Medicine and performed both his internal medicine residency and postgraduate training at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.
Disclosure information not submitted.
FDA Updates and Late Breaking Trials
Thursday, October 23, 2025
8:30 AM – 10:00 AM EDT
Keynote Celebrating 20 Years of CMHC: From Prevention to Treatment to Cure
Thursday, October 23, 2025
10:00 AM – 11:00 AM EDT
Saturday, October 25, 2025
8:30 AM – 8:35 AM EDT
Emerging Therapies in Dyslipidemia: Spotlight on CETP Inhibitors
Saturday, October 25, 2025
9:50 AM – 10:35 AM EDT
FCS, MCS, Persistent Chylomicronemia, sHTG: What do we do now?
Saturday, October 25, 2025
11:05 AM – 11:45 AM EDT
Challenging Lipid Management Cases with Expert Panel Discussion and Audience Q&A
Saturday, October 25, 2025
12:25 PM – 1:40 PM EDT
Saturday, October 25, 2025
1:40 PM – 1:45 PM EDT